inVentiv Health Announces Terrell Herring to Resign

SOMERSET, N.J., Nov. 4, 2009 (GLOBE NEWSWIRE) -- inVentiv Health announced today that Terrell Herring will resign as President and Chief Operating Officer (COO) of inVentiv Health effective December 31, 2009, and join Mission Pharmacal, a growing Texas-based manufacturer of prescription drug products and nutritionals, as President of its Pharmaceutical division. Mission Pharmacal has been an inVentiv client since 2001.

"I am very happy for Terry and wish him great success in his new role with Mission Pharmacal," said Blane Walter, Chief Executive Officer of inVentiv Health. "Over the past 10 years, Terry has helped inVentiv become a formidable competitor. He also has played a critical role in guiding the organization to become more integrated and operationally efficient. I am pleased that Terry will continue to work with us as a client, and that inVentiv will further strengthen our long-standing relationship with Mission Pharmacal under his leadership."

Mr. Herring joined inVentiv Health in 1999 as a National Business Director and, after several promotions, he went on to lead the company's largest division, inVentiv Commercial, as President and CEO. In 2006, he was appointed to inVentiv Health's Board of Directors, and was named President and COO of inVentiv Health in 2008.

Mr. Herring will transition to his new role at Mission Pharmacal in January 2010. He will continue in his position as a Director on inVentiv's Board of Directors.

About inVentiv Health

inVentiv Health, Inc. is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 350 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit www.inventivhealth.com.

The inVentiv Health, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4942

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.

CONTACT:  inVentiv Health, Inc.
          Investors/Corporate:
          David Bassin, CFO
            (732) 537-4804
            investor@inventivhealth.com
          Media:
          Marcia Frederick
            (614) 543-6281
            mfrederick@inventivhealth.com